AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MESO · NASDAQ · Biotechnology

Mesoblast (ADR) (MESO)

Develops FDA-approved Ryoncil for pediatric steroid-refractory acute graft-versus-host disease.

$15.29

After hours−0.02 (−0.13%)

At close$15.31(−3.83%)

Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head Contrast
Defense WorldSep 18
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Seeking AlphaAug 27Earnings
Mesoblast Reports Substantial Revenue Growth to US$120M
GlobeNewsWireAug 26Earnings
Mesoblast H2 Earnings Call Highlights
MarketBeatAug 26
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
Zacks Investment ResearchAug 18Clinical
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
BenzingaAug 17Clinical
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
GlobeNewsWireAug 16
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
GlobeNewsWireJul 29
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
Zacks Investment ResearchJul 17
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
GlobeNewsWireJul 13
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
Seeking AlphaJul 11
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
GlobeNewsWireJul 9
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
GlobeNewsWireApr 29
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
GlobeNewsWireApr 28
Gregory George Acquires 1,981,890 Shares of Mesoblast (NASDAQ:MESO) Stock
Defense WorldApr 12
Gregory George Purchases 4,000,000 Shares of Mesoblast (NASDAQ:MESO) Stock
Defense WorldApr 12
Gregory George Buys 2,324,072 Shares of Mesoblast (NASDAQ:MESO) Stock
Defense WorldApr 12
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
GlobeNewsWireApr 10
Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
Seeking AlphaApr 9
Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)
Seeking AlphaApr 8
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
GlobeNewsWireApr 8
Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
GlobeNewsWireApr 7
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
GlobeNewsWireApr 6
Mesoblast to Host R&D Day on April 8, 2026
GlobeNewsWireMar 17